{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:33:27Z","timestamp":1792784007292,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001582","name":"Dermatology Foundation.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol Myers Squibb, Boehringer Ingelheim, ImClone\/Eli Lilly, Onyx, Bayer, Genzyme, Amgen, and Threshold."},{"name":"Hana Biosciences and Onyx Pharmaceuticals."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jaad.2010.06.051","type":"journal-article","created":{"date-parts":[[2011,7,24]],"date-time":"2011-07-24T17:44:53Z","timestamp":1311529493000},"page":"624-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies"],"prefix":"10.1016","volume":"65","author":[{"given":"Yevgeniy","family":"Balagula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.06.051_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2010.06.051_bib2","first-page":"773","article-title":"Cancer chemotherapy: past, present, and future\u2014Part I","volume":"76","author":"Wright","year":"1984","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jaad.2010.06.051_bib3","series-title":"Cancer-diagnosis and treatment","first-page":"1","article-title":"An introduction to cancer and cancer diagnosis","author":"Slaughter","year":"1959"},{"key":"10.1016\/j.jaad.2010.06.051_bib4","series-title":"The history of cancer therapy. Cancer management: A\u00a0special graduate course on cancer sponsored by the American Cancer Society, Inc","author":"Pack","year":"1968"},{"key":"10.1016\/j.jaad.2010.06.051_bib5","series-title":"Pathfinders in medicine","author":"Robinson","year":"1929"},{"key":"10.1016\/j.jaad.2010.06.051_bib6","series-title":"Die Lehre von der Krebskrankheit von den altesten Zeiten bis zur Gegenwart","author":"Wolff","year":"1907"},{"key":"10.1016\/j.jaad.2010.06.051_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1148\/21.2.156","article-title":"Priority in the therapeutic use of X-rays","volume":"21","author":"Grubbe","year":"1933","journal-title":"Radiology"},{"key":"10.1016\/j.jaad.2010.06.051_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2010.06.051_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.103.2675.409","article-title":"The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides","volume":"103","author":"Gilman","year":"1946","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.06.051_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2010.06.051_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","article-title":"Muromonab CD3. A\u00a0review of its pharmacology and therapeutic potential","volume":"37","author":"Todd","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2010.06.051_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.cr.7310143","article-title":"Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy","volume":"17","author":"Zhang","year":"2007","journal-title":"Cell Res"},{"key":"10.1016\/j.jaad.2010.06.051_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.06.051_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.06.051_bib15","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2010.06.051_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: An update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2010.06.051_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3816\/CBC.2009.n.020","article-title":"Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer","volume":"9","author":"Chin","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib19","unstructured":"Vesanoid (tretinoin) package insert. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20438s004lbl.pdf. Accessed June 15, 2010."},{"key":"10.1016\/j.jaad.2010.06.051_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/archinte.1967.04410010113017","article-title":"Hypersensitivity to nitrogen mustards in the form of erythema multiforme. A\u00a0unique adverse reaction","volume":"120","author":"Brauer","year":"1967","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2010.06.051_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000251603","article-title":"Erythematous eruption of the palms and soles associated with mitotane therapy","volume":"148","author":"Zuehlke","year":"1974","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2010.06.051_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-97-1-61","article-title":"Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia","volume":"97","author":"Burgdorf","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.06.051_bib23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.06.051_bib24","first-page":"494","article-title":"The hand-foot syndrome\u2013a frequent secondary manifestation in antineoplastic chemotherapy","volume":"16","author":"Janusch","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib25","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2010.06.051_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib28","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/jco.2007.25.18_suppl.9007","article-title":"Pyridoxine is not effective for the prevention of hand foot syndrome associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study","volume":"25","author":"Lee","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre","volume":"11","author":"Webster-Gandy","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.jaad.2010.06.051_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archderm.1955.03730320035005","article-title":"Aminopterin for psoriasis","volume":"72","author":"Rees","year":"1955","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.jaad.2010.06.051_bib32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1749-6632.1958.tb42683.x","article-title":"The influence of 1,4-dimethyl sulfonoxy-1,4-dimethylbutane (CB 2348, Dimethyl Myleran) in neoplastic disease","volume":"68","author":"Bierman","year":"1958","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.jaad.2010.06.051_bib33","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11095-006-9105-3","article-title":"Protection against chemotherapy-induced alopecia","volume":"23","author":"Wang","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.jaad.2010.06.051_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1016\/j.jaad.2010.06.051_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-induced alopecia","volume":"28","author":"Trueb","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2010.06.051_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002820-197910000-00004","volume":"2","author":"Wagner","year":"1979","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.jaad.2010.06.051_bib37","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8","article-title":"Adjuvant chemotherapy for breast carcinoma: psychosocial implications","volume":"43","author":"Meyerowitz","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/annonc\/mdi088","article-title":"Prevention of chemotherapy-induced hair loss by scalp cooling","volume":"16","author":"Grevelman","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/oxfordjournals.annonc.a058986","article-title":"Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia","volume":"5","author":"Rodriguez","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-3476(52)80120-9","article-title":"Treatment of acute leukemia in children with and without folic acid antagonists","volume":"41","author":"Poncher","year":"1952","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2010.06.051_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1954.tb40042.x","article-title":"Clinical experience using 6-mercaptopurine in childhood leukemia","volume":"60","author":"Newton","year":"1954","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2010.06.051_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.oraloncology.2010.03.012","article-title":"Oral mucositis","volume":"46","author":"Raber-Durlacher","year":"2010","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib44","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hed.10318","article-title":"Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis","volume":"25","author":"Scully","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.jaad.2010.06.051_bib45","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis","volume":"109","author":"Keefe","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib46","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib47","first-page":"1477","article-title":"Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life","volume":"18","author":"Cheng","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","article-title":"Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review","volume":"66","author":"Trotti","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/1097-0142(1971)28:4<837::AID-CNCR2820280406>3.0.CO;2-4","article-title":"Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease","volume":"28","author":"Wang","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1097-0142(197307)32:1<9::AID-CNCR2820320102>3.0.CO;2-6","article-title":"Adriamycin\u2013an antitumor antibiotic in the treatment of neoplastic diseases","volume":"32","author":"Tan","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib51","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/1097-0142(197609)38:3<1087::AID-CNCR2820380308>3.0.CO;2-X","article-title":"Skin ulcers due to adriamycin","volume":"38","author":"Rudolph","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib52","series-title":"Holland-Frei cancer medicine","article-title":"Dermatologic complications of cancer chemotherapy","author":"Apisarnthanarax","year":"2000"},{"key":"10.1016\/j.jaad.2010.06.051_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1634\/theoncologist.2007-0247","article-title":"Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy","volume":"13","author":"Kane","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2010.06.051_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminoncol.2005.11.004","article-title":"Dermatologic toxicity of chemotherapeutic agents","volume":"33","author":"Payne","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2010.06.051_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib57","first-page":"1191","article-title":"Nail changes due to docetaxel\u2013a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib58","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scotte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib59","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2010.06.051_bib61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2010.06.051_bib62","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib63","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2010.06.051_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.9559","article-title":"Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash","author":"Witherspoon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib65","first-page":"1","article-title":"Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy","volume":"102","author":"Eilers","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2010.06.051_bib66","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaad.2010.06.051_bib67","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib68","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Shu","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib70","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib71","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib72","unstructured":"Sorafenib-induced Hand- Foot Skin Reaction Treatment. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00667589?term=HFSR&rank=1. Accessed Dec 25, 2010."},{"key":"10.1016\/j.jaad.2010.06.051_bib73","first-page":"998","article-title":"Injurious effects on the skin","volume":"1","author":"Stevens","year":"1896","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2010.06.051_bib74","first-page":"106","article-title":"Demonstration eines Cancroid des rechten Handruckens, das sich nach langdauernder Einwirkung von Rontgenstrahlen entwickelt hatte","volume":"6","author":"Frieben","year":"1902","journal-title":"Fortschr Rontgenstr"},{"key":"10.1016\/j.jaad.2010.06.051_bib75","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/01.SMJ.0000140866.97278.87","article-title":"Skin toxicity during breast irradiation: pathophysiology and management","volume":"97","author":"Harper","year":"2004","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2010.06.051_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib77","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0360-3016(00)00782-3","article-title":"Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13","volume":"48","author":"Fisher","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2010.06.051_bib78","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2005.04.9148","article-title":"Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13","volume":"24","author":"Elliott","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14740338.3.6.579","article-title":"Mucocutaneous side effects of antineoplastic chemotherapy","volume":"3","author":"Guillot","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2010.06.051_bib80","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02573889","article-title":"Long-term complications associated with breast-conservation surgery and radiotherapy","volume":"9","author":"Meric","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jaad.2005.08.054","article-title":"Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006","volume":"54","author":"Hymes","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-8140(01)00327-9","article-title":"Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study","volume":"59","author":"Bostrom","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2133.2002.04751.x","article-title":"Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study","volume":"146","author":"Schmuth","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.051_bib85","first-page":"802","article-title":"The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline","volume":"14","author":"Bolderston","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib86","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-04-0658","article-title":"A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy","volume":"10","author":"Metz","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2010.06.051_bib87","unstructured":"Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00801086?term=tempol+alopecia&rank=1. Accessed Dec 25, 2009."},{"key":"10.1016\/j.jaad.2010.06.051_bib88","first-page":"302","article-title":"Secondary lymphedema in the cancer patient","volume":"15","author":"Lacovara","year":"2006","journal-title":"Medsurg Nurs"},{"key":"10.1016\/j.jaad.2010.06.051_bib89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2008.17.9291","article-title":"Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms","volume":"27","author":"Norman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11764-008-0065-y","article-title":"Arm\/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804","volume":"2","author":"Oliveri","year":"2008","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.jaad.2010.06.051_bib91","first-page":"84","article-title":"The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology","volume":"36","year":"2003","journal-title":"Lymphology"},{"key":"10.1016\/j.jaad.2010.06.051_bib92","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/archsurg.133.4.452","article-title":"Effective treatment of lymphedema of the extremities","volume":"133","author":"Ko","year":"1998","journal-title":"Arch Surg"},{"key":"10.1016\/j.jaad.2010.06.051_bib93","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.11641","article-title":"Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial","volume":"98","author":"Carati","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10103-006-0380-3","article-title":"Low-level laser therapy in management of postmastectomy lymphedema","volume":"21","author":"Kaviani","year":"2006","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.jaad.2010.06.051_bib95","unstructured":"MASCC. Available at: http:\/\/www.mascc.org\/Accessed Jan 15, 2010."},{"key":"10.1016\/j.jaad.2010.06.051_bib96","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib97","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.06.051_bib98","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","article-title":"Is there room for improvement in adverse event reporting in the era of targeted therapies?","volume":"100","author":"Edgerly","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2010.06.051_bib99","first-page":"508","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin\u00a0toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2010.06.051_bib100","first-page":"309","article-title":"Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials","volume":"7","author":"Bauer","year":"2008","journal-title":"Clin Colorectal Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210007668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210007668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:19:58Z","timestamp":1759270798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210007668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0190962210007668"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.06.051","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.06.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}